Are the protective effects of SGLT2 inhibitors a "class-effect" or are there differences between agents?

Darren W. Schmidt; Christos Argyropoulos; Namita Singh

doi:10.34067/KID.0000622021

Perspective

Are the protective effects of SGLT2 inhibitors a "class-effect" or are there differences between agents?

Darren W. Schmidt, Christos Argyropoulos and Namita Singh

Kidney360 February 2021, 10.34067/KID.0000622021; DOI: https://doi.org/10.34067/KID.0000622021

Darren W. Schmidt

1Internal Mediicine - Nephrology, University of New Mexico - HSC, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christos Argyropoulos

2University of New Mexico School of Medicine, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Christos Argyropoulos
For correspondence: CArgyropoulos@salud.unm.edu

Namita Singh

2University of New Mexico School of Medicine, United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Namita Singh

Article
Info & Metrics
View PDF

Abstract

This is an Early Access article. Please select the PDF button, above, to view it.

Sodium Glucose Cotransporter Two Inhibitors
Chronic Kidney Disease
Clinical Trials
Class Effects
Heart Failure
SGLT2 inhibitors

Received January 29, 2021.
Revision received February 5, 2021.
Accepted February 5, 2021.

View the discussion thread.

PreviousNext

In this issue

Kidney360

Vol. 2, Issue 2

25 Feb 2021

Table of Contents
Table of Contents (PDF)
Cover (PDF)
About the Cover
Index by author

View Selected Citations (0)

Download PDF

Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Are the protective effects of SGLT2 inhibitors a "class-effect" or are there differences between agents?

Message Subject (Your Name) has sent you a message from American Society of Nephrology

Message Body (Your Name) thought you would like to see the American Society of Nephrology web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Class effects of SGLT2 inhibitors

Darren W. Schmidt, Christos Argyropoulos, Namita Singh

Kidney360 Feb 2021, 10.34067/KID.0000622021; DOI: 10.34067/KID.0000622021

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Request Permissions

Class effects of SGLT2 inhibitors

Darren W. Schmidt, Christos Argyropoulos, Namita Singh

Kidney360 Feb 2021, 10.34067/KID.0000622021; DOI: 10.34067/KID.0000622021

Share This Article:

Tweet Widget
Facebook Like

Jump to section

Article
Info & Metrics
View PDF

Cited By...

No citing articles found.

Google Scholar

Keywords

Sodium Glucose Cotransporter Two Inhibitors
chronic kidney disease
Clinical Trials
Class Effects
Heart Failure
SGLT2 inhibitors

Main menu

User menu

Search

Are the protective effects of SGLT2 inhibitors a "class-effect" or are there differences between agents?

Abstract

In this issue

Citation Manager Formats

More in this TOC Section

Cited By...

Similar Articles

Related Articles

Keywords

Articles

Information for Authors

About

Journal Information

More Information